Wei Kevin S, Lim Alexandra N, Cannon Sophie M
Department of Internal Medicine, Keck School of Medicine at USC, Los Angeles, California.
Division of Endocrinology, Diabetes and Metabolism, UCLA Health, Los Angeles, California.
AACE Clin Case Rep. 2024 Nov 6;11(1):66-69. doi: 10.1016/j.aace.2024.11.002. eCollection 2025 Jan-Feb.
BACKGROUND/OBJECTIVE: Thyrotoxic periodic paralysis (TPP) is a rare condition causing weakness of the lower extremities associated with significant hypokalemia. Likewise, agranulocytosis due to methimazole use is a rare occurrence. We present the first documented case of concomitant TPP and agranulocytosis from methimazole use.
A 48-year-old woman presented with sore throat, fevers, odynophagia, and sudden-onset bilateral leg weakness. Methimazole had been started 10 weeks prior for a new diagnosis of Graves' disease. On admission, the patient was febrile, tachycardic, thyrotoxic, and neutropenic. She also experienced near-paralysis of the lower extremities. She was diagnosed with TPP and treated with beta blockade. She was admitted to the intensive care unit and started on broad-spectrum antibiotics, lithium, and propranolol for treatment of septic shock and hyperthyroidism, respectively. Given persistent hypokalemia despite 2 days of therapy, she was also diagnosed with refeeding syndrome.
TPP is a rare entity, though it should be considered on the differential for any thyrotoxic patient presenting with sudden weakness. If the associated hypokalemia does not begin to normalize within 48 h of beta blockade, other etiologies should be investigated. Lastly, alternative treatments such as lithium may be used to control hyperthyroidism in patients with methimazole-induced agranulocytosis.
While methimazole-induced agranulocytosis and thyrotoxic periodic paralysis are independently rare diagnoses, the combination of the 2 is exceedingly rare, and our case represents the first documented case in the literature reflecting a patient suffering from both syndromes.
背景/目的:甲状腺毒症性周期性瘫痪(TPP)是一种罕见病症,会导致下肢无力并伴有严重低钾血症。同样,使用甲巯咪唑导致粒细胞缺乏症的情况也很罕见。我们报告首例有记录的因使用甲巯咪唑而同时发生TPP和粒细胞缺乏症的病例。
一名48岁女性出现咽痛、发热、吞咽痛以及突发双侧腿部无力。10周前因新诊断的格雷夫斯病开始使用甲巯咪唑。入院时,患者发热、心动过速、甲状腺毒症且中性粒细胞减少。她还出现了下肢近乎瘫痪的症状。她被诊断为TPP并接受β受体阻滞剂治疗。她被收入重症监护病房,分别开始使用广谱抗生素、锂盐和普萘洛尔治疗感染性休克和甲状腺功能亢进症。尽管治疗2天后仍持续存在低钾血症,但她也被诊断为再喂养综合征。
TPP是一种罕见病症,不过对于任何出现突发无力的甲状腺毒症患者,都应将其列入鉴别诊断范围。如果在使用β受体阻滞剂48小时内相关低钾血症未开始恢复正常,则应调查其他病因。最后,对于甲巯咪唑诱发粒细胞缺乏症的患者,可使用锂盐等替代疗法来控制甲状腺功能亢进。
虽然甲巯咪唑诱发的粒细胞缺乏症和甲状腺毒症性周期性瘫痪各自都是罕见诊断,但两者同时出现极为罕见,我们的病例是文献中首例记录的同时患有这两种综合征的患者。